Alyssa Rapp (L) and Greg Simon
One SPAC inks biotech merger, while another linked to former Biden cancer moonshot leader will shut down
A biotech looking to make approved drugs safer and expand them into new indications has lined up a SPAC merger. Meanwhile, a blank-check from the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
